Johnson & Johnson (TSX:JNJ)
Canada · Delayed Price · Currency is CAD | Market Cap | 808.13B +52.0% |
| Revenue (ttm) | 128.76B +6.0% |
| Net Income | 36.64B +90.6% |
| EPS | 15.08 +90.5% |
| Shares Out | n/a |
| PE Ratio | 22.06 |
| Forward PE | 21.03 |
| Dividend | 0.67 (2.11%) |
| Ex-Dividend Date | Feb 24, 2026 |
| Volume | 3,759 |
| Average Volume | 8,851 |
| Open | 31.64 |
| Previous Close | 31.73 |
| Day's Range | 31.37 - 31.64 |
| 52-Week Range | 18.90 - 31.91 |
| Beta | n/a |
| RSI | 71.66 |
| Earnings Date | Apr 14, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial numbers in USD Financial StatementsNews
2 Dividend Kings That Could Easily Keep The Growth Streak Alive
We are looking at a screening process to sort out and look for some potential opportunities in the elite group known as the dividend kings. Dividend growers can help investors combat the erosion of bu...
Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer
Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3 Data highlight the potential of this first-in-class next-generation T-cell engager to expand...
Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)
Data from the pivotal ENERGY trial showed IMAAVY® produced a rapid and durable hemoglobin responsea in wAIHA Currently no FDA-approved therapies are available for wAIHA, a rare, heterogeneous, life-th...
Does JNJ Stock Still Offer Value?
Up 17% through February 2026, Johnson & Johnson stock (NYSE: JNJ) is riding a wave of momentum fueled by a "triple threat" of high-growth oncology sales, a massive MedTech rebound, and a surprise earn...
Bayer files lawsuit against Johnson & Johnson, Janssen Biotech
German pharmaceutical company Bayer said on Monday that it had filed a lawsuit in a New York court against Johnson & Johnson and Janssen Biotech Inc related to its Nubeqa prostate cancer drug.
Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that it has filed suit against Johnson & Johnson (J&J) and Janssen Biotech, Inc. in the United States District Court for the Southern District of...
TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years
More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension study, showing lasting disease cont...
Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)
Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer
Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO™; results surpass current standards of care RARITAN, N.J., Feb. 19, 2026 /PRNewswire/ -- Johnson & Jo...
Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports
Johnson & Johnson is preparing a potential sale of the orthopedics unit that it has been planning to separate, with big buyout firms already circling, Bloomberg News reported on Thursday, citing peopl...
Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility
Johnson & Johnson announced a $1 billion investment in a Montgomery County, Pennsylvania, cell therapy facility that will yield over 500 manufacturing jobs plus 4,000 construction jobs.
Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory
The facility is part of the company's plans to invest $55 billion in U.S. manufacturing, research and development and technology through early 2029.
J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push
Johnson & Johnson said on Wednesday it will invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of its larger plans announced last year to scale up U.S. manufacturin...
Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare's leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment i...
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO™ beyond lung cancer RARITAN, N.J., Feb. 18, ...
FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2 Builds on RYBREVANT FASPRO™ FDA approval to deliver the simplest and fastest combination regimen for EGFR+ ...
Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K
The plaintiff used J&J's baby powder from 1969 until 2017. She sued in 2019 and died six months later at the age of 68.
Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial
PHILADELPHIA--(BUSINESS WIRE)--A jury in the Philadelphia Court of Common Pleas has found Johnson & Johnson (NYSE:JNJ) responsible for the company's baby powder products contributing to the death of a...
Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial
A jury in Pennsylvania state court on Friday awarded $250,000 to the family of a woman who sued Johnson & Johnson alleging its talc-based baby powder was to blame for her ovarian cancer, according to ...
After A 55% Surge, Is JNJ Stock Still A Buy?
Johnson & Johnson (JNJ) stock is currently at a notable juncture. It exhibits strong momentum, up 55% in the last twelve months, and investing in it entails support for a company characterized by robu...
NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review
The National Institutes of Health (NIH) on Tuesday discontinued the low-dose rivaroxaban arm of its ongoing Phase 3 CAPTIVA stroke prevention trial.
Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10th, 2026. Management will participate in a...
Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium
IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson announced 12-month pilot-phase data from the OMNY-AF study and highlighted new findings related to the VARIPULSE Platform.